The European Commission's Spring 2026 Economic Forecast projects a 1.2% decline in Irish gross domestic product (GDP) for 2026, primarily attributed to the frontloading of pharmaceutical exports in 2025.
According to the forecast, the contraction is largely a statistical effect, as multinational pharmaceutical firms shifted production and exports forward into 2025, creating a high base for comparison. The Commission notes that underlying domestic economic activity, as measured by modified domestic demand, is expected to grow modestly.
Ireland's economy remains heavily influenced by the activities of multinational corporations, particularly in the pharmaceutical and technology sectors. The forecast highlights that GDP volatility is common in Ireland due to these factors.
The Commission expects GDP growth to resume in 2027, with a projected increase of 2.3%, as the pharmaceutical sector normalizes and other sectors continue to expand.
